Understanding The Role of MIR93 in Cancer and Aging (G407050)

Target Name: MIR93

NCBI ID: G407050

MIR93

Understanding The Role of MIR93 in Cancer and Aging

MIR93 (MIRN93), a small non-coding RNA (ncRNA), has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure, function, and expression patterns make it an attractive target for researchers to study.

MIR93 is a non-coding RNA molecule that contains 19 amino acid residues. It is expressed in various tissues and organs, including brain, heart, liver, and muscle. It has been shown to play a role in various cellular processes, including cell adhesion , migration, and invasion.

One of the most significant features of MIR93 is its ability to interact with various proteins. It has been shown to interact with several proteins, including the transcription factor NF-kappa-B and the protein tyrosine kinase FAK. These interactions may regulate various cellular processes and contribute to MIR93's function as a drug target.

MIR93 has also been shown to be involved in the regulation of cellular processes that are important in cancer development. For example, MIR93 has been shown to be involved in the regulation of cell cycle progression, which is a critical process in cancer development.

In addition to its involvement in cell cycle regulation, MIR93 has also been shown to play a role in the regulation of apoptosis (programmed cell death). Apoptosis is a natural process that helps remove damaged or dysfunctional cells from the body, and it is important for maintaining tissue homeostasis. However, cancer cells often use apoptosis as a mechanism to evade the immune system and continue to divide.

MIR93 has been shown to be involved in the regulation of apoptosis by activating the Bcl-2 protein. Bcl-2 is a protein that has been shown to promote the survival of many types of tumor cells. MIR93 has been shown to induce Bcl-2 protein expression in cancer cells, which may contribute to its role in cancer cell survival.

Another potential mechanism by which MIR93 may contribute to cancer development is its role in cell-cell signaling. MIR93 has been shown to interact with several proteins, including the protein Src. Src is a transmembrane protein that is involved in a variety of cellular processes, including cell-cell signaling.

MIR93 has been shown to play a role in cell-cell signaling by regulating the activity of the protein tyrosine kinase (TK) kinase. TK kinase is a protein that is involved in the regulation of many cellular processes, including cell-cell signaling. MIR93 has been shown to regulate the activity of TK kinase, which may contribute to its role in cell-cell signaling.

In addition to its role in cell-cell signaling, MIR93 may also contribute to cancer development by regulating gene expression. MIR93 has been shown to interact with the protein Myb, which is involved in the regulation of gene expression.

MIR93 has also been shown to play a role in the regulation of cellular processes that are important in aging and age-related diseases. For example, MIR93 has been shown to be involved in the regulation of the protein p21, which is involved in the regulation of cell cycle progression and apoptosis.

In conclusion, MIR93 is a non-coding RNA molecule that has been shown to play a role in various cellular processes, including cell adhesion, migration, and invasion. Its unique structure, function, and expression patterns make it an attractive target for researchers to study. Its ability to interact with various proteins and its involvement in cell cycle regulation, apoptosis, and cell-cell signaling may make it a valuable drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of MIR93 in these diseases.

Protein Name: MicroRNA 93

The "MIR93 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR93 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets